Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD (WISDOM)
Source: View publication →
In patients with severe COPD, the stepwise withdrawal of inhaled glucocorticoids while continuing dual bronchodilator therapy did not increase the risk of moderate or severe exacerbations, though it led to a small decrease in lung function.
Key Findings
Study Design
Study Limitations
Clinical Significance
The WISDOM trial challenged the longstanding practice of indefinite inhaled corticosteroid (ICS) use for all patients with severe COPD. By demonstrating that ICS could be safely de-escalated in patients receiving optimal dual long-acting bronchodilator therapy (LABA/LAMA) without increasing the risk of exacerbations, the trial provided a framework to reduce the long-term adverse effects of ICS, such as pneumonia and bone density loss. It laid the foundation for modern personalized COPD management, wherein ICS therapy is targeted primarily to patients with specific traits, such as elevated blood eosinophils or a history of recurrent exacerbations despite maximal bronchodilation.
Historical Context
Prior to 2014, clinical guidelines broadly recommended the addition of inhaled corticosteroids to bronchodilators for patients with severe COPD and a history of frequent exacerbations. However, as evidence grew regarding the efficacy of combined long-acting beta-agonists (LABA) and long-acting muscarinic antagonists (LAMA) in preventing exacerbations, the additive value of ICS became questionable. Simultaneously, concerns were mounting over the well-documented side effects of prolonged ICS use in older adults. The WISDOM trial was designed to formally investigate whether de-prescribing ICS in the context of robust dual bronchodilator therapy was a safe and viable strategy.
Guided Discussion
High-yield insights from every perspective
What is the pathophysiological rationale for using inhaled corticosteroids in COPD, and how does the underlying inflammation in COPD differ from that in asthma, potentially explaining the findings of the WISDOM trial?
Key Response
Asthma is typically characterized by eosinophilic, Th2-driven inflammation which is highly responsive to corticosteroids. In contrast, COPD is predominantly driven by neutrophilic, CD8+ T-cell, and macrophage-mediated inflammation triggered by irritants like smoking, which is relatively corticosteroid-resistant. This fundamental difference explains why stepping down ICS in COPD may not significantly worsen exacerbation risk, whereas it would be detrimental in asthma.
A patient with severe COPD is currently stable on triple therapy (ICS/LABA/LAMA). Based on the WISDOM trial, you consider withdrawing the ICS. What specific adverse effects of long-term ICS use justify this de-escalation, and what parameters should you monitor during the withdrawal process?
Key Response
Long-term ICS use in COPD is associated with an increased risk of pneumonia, oral candidiasis, osteoporosis, skin bruising, and potentially mycobacterial infections. The WISDOM trial demonstrated that ICS can be withdrawn without increasing exacerbation risk, but since there was a minor drop in FEV1, clinicians should monitor spirometry and symptoms to ensure the patient tolerates the transition to dual bronchodilator therapy.
Post-hoc analyses of the WISDOM trial and subsequent studies emphasize the role of peripheral blood eosinophils. How does the blood eosinophil count modify the risk of exacerbation upon ICS withdrawal, and how should a pulmonologist use this biomarker to select candidates for ICS de-escalation?
Key Response
Subsequent analyses showed that patients with higher blood eosinophil counts (e.g., greater than or equal to 300 cells/microL) are at a higher risk of exacerbation if ICS is withdrawn. Pulmonologists use eosinophil counts as a biomarker for Th2-mediated inflammation in COPD; patients with high counts benefit from continued ICS, whereas those with low counts are ideal candidates for ICS withdrawal.
The WISDOM trial revealed a statistically significant decline in FEV1 after ICS withdrawal, yet no increase in exacerbations. How do you reconcile discordant FEV1 and exacerbation outcomes when counseling patients and junior trainees about the clinical meaning of 'stability' in COPD?
Key Response
FEV1 is a surrogate physiological marker that does not perfectly correlate with clinical outcomes like exacerbation frequency, dyspnea, or quality of life in COPD. The trial teaches that a marginal drop in FEV1 (about 43 mL) may not be clinically relevant or translate to increased exacerbations when patients are covered by dual bronchodilation. We must treat the patient's clinical risk, not just the spirometry numbers.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The WISDOM trial utilized a non-inferiority design for its primary endpoint. What are the methodological challenges in defining the non-inferiority margin for COPD exacerbations, and how might the 'stepwise' withdrawal design introduce bias compared to an abrupt cessation model?
Key Response
Selecting a non-inferiority margin requires balancing statistical feasibility with clinical relevance (WISDOM used a hazard ratio upper bound of 1.20). Methodologically, a stepwise withdrawal mimics clinical practice but complicates the isolation of the exact time point when drug withdrawal effects occur, potentially delaying the observation of exacerbations due to a prolonged washout period, thus biasing the results toward non-inferiority.
As a peer reviewer, how would you critically evaluate the generalizability of the WISDOM trial given that all patients underwent a 6-week run-in period on triple therapy before randomization, and how might this 'enrichment' strategy mask the true effect of ICS withdrawal in a real-world unselected population?
Key Response
The run-in period stabilizes all patients on triple therapy, ensuring compliance but also potentially selecting for a cohort that is inherently stable and responsive. A tough reviewer would flag that withdrawing ICS in patients who have been artificially stabilized might underestimate the withdrawal risks compared to real-world patients who have fluctuating adherence or distinct exacerbation phenotypes not captured by the inclusion criteria.
How do the findings of the WISDOM trial influence the GOLD (Global Initiative for Chronic Obstructive Lung Disease) guideline recommendations regarding the de-escalation of triple therapy, specifically concerning the strength of recommendation for using LABA/LAMA combinations over continued ICS use?
Key Response
The WISDOM trial provided pivotal evidence for GOLD guidelines to recommend ICS withdrawal (stepping down to LABA/LAMA) in patients without frequent exacerbations and low eosinophils. Current GOLD guidelines support de-escalation for patients who lack asthma history and have eosinophils less than 300 cells/microL to mitigate pneumonia risk. The trial supports a strong recommendation for dual bronchodilator maintenance as sufficient for exacerbation prevention in this specific low-eosinophil phenotype.
Clinical Landscape
Noteworthy Related Trials
TORCH Trial
Tested
Salmeterol/fluticasone (LABA/ICS)
Population
Patients with moderate-to-severe COPD
Comparator
Placebo, salmeterol alone, or fluticasone alone
Endpoint
All-cause mortality at 3 years
FLAME Trial
Tested
Indacaterol/glycopyrronium (LABA/LAMA)
Population
COPD patients with at least 1 exacerbation in the previous year
Comparator
Salmeterol/fluticasone (LABA/ICS)
Endpoint
Annual rate of all COPD exacerbations
IMPACT Trial
Tested
Fluticasone furoate/umeclidinium/vilanterol (ICS/LAMA/LABA)
Population
Symptomatic COPD patients with a history of exacerbations
Comparator
ICS/LABA or LAMA/LABA
Endpoint
Annual rate of moderate or severe COPD exacerbations
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis